{"nct_id":"NCT05665595","title":"A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-08","start_date":"2023-01-19","start_date_type":"ACTUAL","primary_completion_date":"2024-03-06","primary_completion_date_type":"ACTUAL","completion_date":"2025-09-26","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["MRK"]}